Category: Lung Cancer

ADAO Praises U.S. Senate for Passing Senator Patty Murray’s Ban Asbestos in America Act The Asbestos Disease Awareness Organization (ADAO), an organization dedicated to serving as the voice of asbestos victims, praised the passage of Senator Patty Murray (D-WA)’s Ban Asbestos in America Act of 2007 by the U.S. Senate.

Determining the genetic profile of a particular lung tumor can help clinicians make the crucial decision about which chemotherapy treatment to try first.A new study led by researchers from the Duke University Comprehensive Cancer Center and the Duke Institute for Genome Sciences & Policy (IGSP) found distinct differences in the susceptibility different tumors have to widely used chemotherapy drugs.

The Society for Women’s Health Research gathered three lung cancer experts on Capitol Hill on September 17, 2007 to inform Congress on the need for increased funding to research lung cancer and its impact on women. “We focused on lung cancer today because lung cancer is the leading cause of cancer death for both women and men in America,” said Phyllis Greenberger, M.S.W, president and CEO of the Society, a Washington, D.C. based advocacy organization.

Researchers have found that the breast cancer susceptibility gene, BRCA1, plays a significant role in non-small cell lung cancer (NSCLC). Not only can it be used to predict outcome for patients with NSCLC, but it may also prove to be a valuable tool in choosing the best therapy for them.

In clinical research, patients with advanced non-small cell lung cancer (NSCLC) that are classified as having a non-squamous histology achieve statistically significant higher survival when treated in the second-line setting with ALIMTA(R) (pemetrexed for injection) when compared to histologically-similar patients treated with docetaxel. The data (ECCO Abstract # 6521)(1) were presented at the 14th European Cancer Conference ECCO) in Barcelona.

In clinical research, patients with advanced non-small cell lung cancer (NSCLC) that are classified as having a non-squamous histology achieve statistically significant higher survival when treated in the second-line setting with ALIMTA(R) (pemetrexed for injection) when compared to histologically-similar patients treated with docetaxel. The data (ECCO Abstract # 6521)(1) were presented at the 14th European Cancer Conference ECCO) in Barcelona.

Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) announced that the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone.

Results published in the Journal of Clinical Oncology1 show that AstraZeneca’s investigational once-daily oral anti-cancer drug vandetanib in combination with docetaxel, increased progression free survival (PFS) compared with docetaxel alone in a phase II study of 127 patients with pre-treated advanced Non-Small Cell Lung Cancer (NSCLC). The trial, study 6 demonstrated that adding vandetanib 100mg to standard docetaxel therapy improved median PFS to 18.7 weeks (HR=0.

When it is quiet — “almost too quiet” — in movies, it is a sign that something is about to go wrong for the good guys. This holds true for the genes that protect against lung cancer, as researchers at the University of Toledo in Toledo, Ohio, have learned.

While the American College of Chest Physicians (ACCP) came out last week in opposition to CT screening for lung cancer, Lung Cancer Alliance (LCA) reiterated its support for the screening test which can detect lung cancer at its earliest most treatable stage for those at high risk. “Mammograms for breast cancer faced enormous opposition for decades and there is still heated debate over screening of women under the age of 50.